Login to Your Account

Oral Version Hedges Bet

I.V. Chemo Payouts Staying Put, Poniard Poises for Big-time Profits

By Randy Osborne

Monday, August 10, 2009
The trim-down tactics this spring by Poniard Pharmaceuticals Inc. to pump more thrust behind the Phase III SPEAR trial put most of the company's oomph behind its "pipeline-in-a-drug" candidate picoplatin, and easily could lead to an acquisition after data roll out by the end of this year.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription